Development  ||| S:0 E:12 ||| NN
of  ||| S:12 E:15 ||| IN
inhibitors  ||| S:15 E:26 ||| NN
in  ||| S:26 E:29 ||| IN
haemophilia ||| S:29 E:40 ||| NN
.  ||| S:40 E:42 ||| .
Ongoing  ||| S:42 E:50 ||| JJ
epidemiological  ||| S:50 E:66 ||| NNS
study  ||| S:66 E:72 ||| VBP
A  ||| S:72 E:74 ||| DT
number  ||| S:74 E:81 ||| NN
of  ||| S:81 E:84 ||| IN
513  ||| S:84 E:88 ||| CD
consecutive  ||| S:88 E:100 ||| JJ
patients  ||| S:100 E:109 ||| NNS
( ||| S:109 E:110 ||| -LRB-
494-haemophilia  ||| S:110 E:126 ||| NNP
A  ||| S:126 E:128 ||| NNP
and  ||| S:128 E:132 ||| CC
19-haemophilia  ||| S:132 E:147 ||| NNP
B ||| S:147 E:148 ||| NNP
)  ||| S:148 E:150 ||| -RRB-
from  ||| S:150 E:155 ||| IN
eight  ||| S:155 E:161 ||| CD
haemophilia  ||| S:161 E:173 ||| JJ
treatment  ||| S:173 E:183 ||| NN
centers  ||| S:183 E:191 ||| NNS
have  ||| S:191 E:196 ||| VBP
been  ||| S:196 E:201 ||| VBN
investigated  ||| S:201 E:214 ||| VBN
with  ||| S:214 E:219 ||| IN
Bethesda  ||| S:219 E:228 ||| NNP
assay  ||| S:228 E:234 ||| NN
for  ||| S:234 E:238 ||| IN
the  ||| S:238 E:242 ||| DT
presence  ||| S:242 E:251 ||| NN
of  ||| S:251 E:254 ||| IN
factor  ||| S:254 E:261 ||| NN
VIII  ||| S:261 E:266 ||| NNP
or  ||| S:266 E:269 ||| CC
IX  ||| S:269 E:272 ||| CD
inhibitors ||| S:272 E:282 ||| NNS
.  ||| S:282 E:284 ||| .
The  ||| S:284 E:288 ||| DT
overall  ||| S:288 E:296 ||| JJ
prevalence  ||| S:296 E:307 ||| NN
of  ||| S:307 E:310 ||| IN
inhibitors  ||| S:310 E:321 ||| NN
was  ||| S:321 E:325 ||| VBD
15.20 ||| S:325 E:330 ||| CD
% ||| S:330 E:331 ||| NN
,  ||| S:331 E:333 ||| ,
18.48 ||| S:333 E:338 ||| CD
%  ||| S:338 E:340 ||| NN
in  ||| S:340 E:343 ||| IN
severe ||| S:343 E:349 ||| JJ
,  ||| S:349 E:351 ||| ,
5.60 ||| S:351 E:355 ||| CD
%  ||| S:355 E:357 ||| NN
in  ||| S:357 E:360 ||| IN
moderate  ||| S:360 E:369 ||| JJ
and  ||| S:369 E:373 ||| CC
12.24 ||| S:373 E:378 ||| CD
%  ||| S:378 E:380 ||| NN
in  ||| S:380 E:383 ||| IN
mild  ||| S:383 E:388 ||| JJ
forms ||| S:388 E:393 ||| NNS
.  ||| S:393 E:395 ||| .
The  ||| S:395 E:399 ||| DT
prevalence  ||| S:399 E:410 ||| NN
was  ||| S:410 E:414 ||| VBD
higher  ||| S:414 E:421 ||| JJR
than  ||| S:421 E:426 ||| IN
reported  ||| S:426 E:435 ||| VBN
in  ||| S:435 E:438 ||| IN
most  ||| S:438 E:443 ||| JJS
of  ||| S:443 E:446 ||| IN
the  ||| S:446 E:450 ||| DT
western  ||| S:450 E:458 ||| JJ
countries ||| S:458 E:467 ||| NNS
.  ||| S:467 E:469 ||| .
The  ||| S:469 E:473 ||| DT
age  ||| S:473 E:477 ||| NN
at  ||| S:477 E:480 ||| IN
start  ||| S:480 E:486 ||| NN
of  ||| S:486 E:489 ||| IN
substitution  ||| S:489 E:502 ||| NNS
( ||| S:502 E:503 ||| -LRB-
p  ||| S:503 E:505 ||| CD
=  ||| S:505 E:507 ||| SYM
0.9775 ||| S:507 E:513 ||| CD
) ||| S:513 E:514 ||| -RRB-
,  ||| S:514 E:516 ||| ,
the  ||| S:516 E:520 ||| DT
frequent  ||| S:520 E:529 ||| JJ
switching  ||| S:529 E:539 ||| NN
of  ||| S:539 E:542 ||| IN
factor  ||| S:542 E:549 ||| NN
concentrates  ||| S:549 E:562 ||| NNS
( ||| S:562 E:563 ||| -LRB-
p  ||| S:563 E:565 ||| CD
=  ||| S:565 E:567 ||| SYM
0.8931 ||| S:567 E:573 ||| CD
)  ||| S:573 E:575 ||| -RRB-
were  ||| S:575 E:580 ||| VBD
not  ||| S:580 E:584 ||| RB
relevant  ||| S:584 E:593 ||| JJ
factors  ||| S:593 E:601 ||| NNS
for  ||| S:601 E:605 ||| IN
the  ||| S:605 E:609 ||| DT
development  ||| S:609 E:621 ||| NN
of  ||| S:621 E:624 ||| IN
inhibitors ||| S:624 E:634 ||| NN
.  ||| S:634 E:636 ||| .
It  ||| S:636 E:639 ||| PRP
is  ||| S:639 E:642 ||| VBZ
worth  ||| S:642 E:648 ||| JJ
to  ||| S:648 E:651 ||| TO
be  ||| S:651 E:654 ||| VB
mentioned  ||| S:654 E:664 ||| VBN
the  ||| S:664 E:668 ||| DT
unexpectedly  ||| S:668 E:681 ||| JJ
occurrence  ||| S:681 E:692 ||| NN
of  ||| S:692 E:695 ||| IN
inhibitors  ||| S:695 E:706 ||| NN
in  ||| S:706 E:709 ||| IN
prior  ||| S:709 E:715 ||| JJ
inhibitor  ||| S:715 E:725 ||| JJ
negative  ||| S:725 E:734 ||| JJ
( ||| S:734 E:735 ||| -LRB-
6 ||| S:735 E:736 ||| CD
/ ||| S:736 E:737 ||| CD
72 ||| S:737 E:739 ||| CD
)  ||| S:739 E:741 ||| -RRB-
patients  ||| S:741 E:750 ||| NNS
( ||| S:750 E:751 ||| -LRB-
during  ||| S:751 E:758 ||| IN
surgical  ||| S:758 E:767 ||| JJ
interventions ||| S:767 E:780 ||| NNS
)  ||| S:780 E:782 ||| -RRB-
probably  ||| S:782 E:791 ||| RB
due  ||| S:791 E:795 ||| JJ
to  ||| S:795 E:798 ||| TO
their  ||| S:798 E:804 ||| PRP$
previous  ||| S:804 E:813 ||| JJ
scarce  ||| S:813 E:820 ||| JJ
substitution ||| S:820 E:832 ||| NN
,  ||| S:832 E:834 ||| ,
occurrence  ||| S:834 E:845 ||| NN
which  ||| S:845 E:851 ||| WDT
seems  ||| S:851 E:857 ||| VBZ
not  ||| S:857 E:861 ||| RB
being  ||| S:861 E:867 ||| VBG
connected  ||| S:867 E:877 ||| VBN
with  ||| S:877 E:882 ||| IN
the  ||| S:882 E:886 ||| DT
continuous  ||| S:886 E:897 ||| JJ
infusion  ||| S:897 E:906 ||| NN
modality  ||| S:906 E:915 ||| NN
of  ||| S:915 E:918 ||| IN
factor  ||| S:918 E:925 ||| NN
VIII  ||| S:925 E:930 ||| NNP
administration  ||| S:930 E:945 ||| NN
( ||| S:945 E:946 ||| -LRB-
p  ||| S:946 E:948 ||| CD
=  ||| S:948 E:950 ||| SYM
0.8341 ||| S:950 E:956 ||| CD
) ||| S:956 E:957 ||| -RRB-
.  ||| S:957 E:959 ||| .
In  ||| S:959 E:962 ||| IN
controversial  ||| S:962 E:976 ||| JJ
situations ||| S:976 E:986 ||| NNS
,  ||| S:986 E:988 ||| ,
in  ||| S:988 E:991 ||| IN
the  ||| S:991 E:995 ||| DT
field  ||| S:995 E:1001 ||| NN
of  ||| S:1001 E:1004 ||| IN
low  ||| S:1004 E:1008 ||| JJ
titer  ||| S:1008 E:1014 ||| NNS
( ||| S:1014 E:1015 ||| -LRB-
â‰¤  ||| S:1015 E:1017 ||| CD
1  ||| S:1017 E:1019 ||| CD
BU ||| S:1019 E:1021 ||| CD
/ ||| S:1021 E:1022 ||| CD
ml ||| S:1022 E:1024 ||| CD
)  ||| S:1024 E:1026 ||| -RRB-
inhibitors  ||| S:1026 E:1037 ||| NN
for  ||| S:1037 E:1041 ||| IN
a  ||| S:1041 E:1043 ||| DT
reliable  ||| S:1043 E:1052 ||| JJ
interpretation  ||| S:1052 E:1067 ||| NN
of  ||| S:1067 E:1070 ||| IN
the  ||| S:1070 E:1074 ||| DT
results  ||| S:1074 E:1082 ||| NNS
the  ||| S:1082 E:1086 ||| DT
performance  ||| S:1086 E:1098 ||| NN
of  ||| S:1098 E:1101 ||| IN
recovery  ||| S:1101 E:1110 ||| NN
index  ||| S:1110 E:1116 ||| NN
and  ||| S:1116 E:1120 ||| CC
half-life  ||| S:1120 E:1130 ||| NN
time  ||| S:1130 E:1135 ||| NN
assessment  ||| S:1135 E:1146 ||| NN
of  ||| S:1146 E:1149 ||| IN
FVIII ||| S:1149 E:1154 ||| NNP
/ ||| S:1154 E:1155 ||| NNP
IX  ||| S:1155 E:1158 ||| NNP
was  ||| S:1158 E:1162 ||| VBD
undertaken ||| S:1162 E:1172 ||| VBN
.  ||| S:1172 E:1174 ||| .
